Please assess the completion status of the following clinical trial:

Trial Title: Research in Severe Asthma (RISA) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory adult; age 18-65 years~* Asthma requiring regular maintenance medication that includes high dose inhaled corticosteroid AND long acting β2 agonist (LABA) with or without other asthma maintenance medications. Oral prednisone ≤30 mg/day, leukotriene modifiers, theophylline or other asthma control drugs may be prescribed at the physician's discretion.~* Pre-bronchodilator forced expiratory volume in one second (FEV1) ≥50% predicted (patients stabilized on inhaled corticosteroids (ICS) and long acting β2 agonists)~* PC20 \< 4 mg/ml per methacholine inhalation test using standardized methods, for patients with pre-bronchodilator FEV1 ≥60% predicted (or FEV1 \> lower limit defined by individual hospital protocol). PC20 is the provocative concentration of Provocholine® (a brand of methacholine chloride) resulting in a drop of FEV1 of 20% or more from Baseline~* Reversible bronchoconstriction during the 12 months prior to enrollment, as demonstrated by an increase in FEV1 of at least 12% 30 minutes after 4 puffs of short-acting β2 agonist, for patients with pre-bronchodilator FEV1 \< 60% predicted (or FEV1 \< lower limit defined by individual hospital protocol)~* Patient must be symptomatic, despite medication with high dose inhaled corticosteroids and LABA, by at least one of the following:~  1. Use of rescue medication (short-acting β2 agonist) at least 8 of the 14 days prior to enrollment OR~ 2. Daytime symptoms at least 10 of the 14 days prior to enrollment~* Non-smoker x 1 year or greater (if former smoker, less than 10 pack years total smoking history)~* Patient must be suitable for bronchoscopy in the opinion of the investigator or per hospital guidelines~* Willingness and ability to give written Informed Consent~* Willingness and ability to comply with the study protocol, including requirements for taking and abstaining from medications~Exclusion Criteria:~* Participation in another clinical trial involving respiratory intervention that could affect the outcome measures of this study, within 6 weeks prior to randomization. Patients will be disqualified from the study if they enter another study or fail to comply with prescribed asthma medications.~* Use of immunosuppressant therapy (e.g., methotrexate).~* Current or recent lower respiratory tract infection (resolved less than 6 weeks from enrollment testing)~* History of recurrent (no more than three in the last three months) lower respiratory tract infection requiring antibiotics~* Presence of other respiratory diseases including emphysema, cystic fibrosis, vocal cord dysfunction, mechanical upper airway obstruction, obstructive sleep apnea, Churg-Strauss syndrome, cardiac dysfunction, allergic bronchopulmonary aspergillosis~* DLCO (diffusion capacity) \< 70% predicted~* Uncontrolled sinus disease~* Uncontrolled gastro-esophageal reflux disease~* Use of implanted electronic device such as a pacemaker or internal cardiac defibrillator~* Use of external pacemaker~* Significant co-morbid illness such as cancer, renal failure, liver disease or cerebral vascular disease~* Post-bronchodilator FEV1 of less than 55% predicted~* Known systemic hypersensitivity or contraindication to methacholine chloride or other parasympathomimetic agents~* Known sensitivity to medications required to perform bronchoscopy, including lidocaine, atropine, benzodiazepines and opioids~* Use of a systemic b-adrenergic blocking agent~* Other medical criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day.
- Control (Type: ACTIVE_COMPARATOR): Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).